Findings

What do systematic reviews say?

1,271 questions · 1,326 findings · 329 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 247 · 18.6%GRADE not reported 237 · 17.9%Very low 379 · 28.6%Low 285 · 21.5%Moderate 141 · 10.6%High 37 · 2.8%

Amantadine vs placebo

Fatigue · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Change in activity limitations · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Participation · people with fatigue in Guillain‐Barré syndrome

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
74 participants
Low

Amantadine vs placebo

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ascorbic acid vs placebo

Fatigue · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 404 participants
Moderate

Endoscopic vs open or mini‐open carpal tunnel release

Overall improvement at more than 3 months Participants' subjective evaluation · carpal tunnel syndrome

Endoscopic showed no clear difference in overall improvement at more than 3 months Participants' subjective… compared with open or mini‐open carpal tunnel release (low certainty).

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
RR 1.04 [0.95, 1.14]
4 studies · 317 participants
Low

Endoscopic vs open or mini‐open carpal tunnel release

Symptom Severity Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 273 participants
Low

Endoscopic vs open or mini‐open carpal tunnel release

Function Status Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 273 participants
Low

Endoscopic vs open or mini‐open carpal tunnel release

Grip strength ‐ Vitamin D · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 56 participants
Low

Intervention not reported

Long‐term complications (one year or more after surgery) · people with age‐related cataract

The review found no eligible studies for this question.

1 finding from 1 review

Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract… 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Very low

Riluzole vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Physiotherapy and occupational therapy vs placebo

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Betamethasone vs placebo

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
13 participants
Moderate

Tiotropium vs placebo

Exacerbations (number of people experiencing ≥ 1 exacerbations) · people with COPD who have smoked for ≥ 10 pack‐years

Tiotropium leads to lower number of patients with one or more exacerbations compared with placebo (high certainty).

1 finding from 1 review

Tiotropium versus placebo for chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.78 [0.7, 0.87]
22 studies · 23309 participants
High

Tiotropium vs placebo

Hospital admissions due to exacerbations: number of participants · people with COPD who have smoked for ≥ 10 pack‐years

Tiotropium showed no clear difference in number of patients with one or more exacerbations requiring… compared with placebo (moderate certainty).

1 finding from 1 review

Tiotropium versus placebo for chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.85 [0.72, 1]
21 studies · 22852 participants
Moderate

Tiotropium vs placebo

Hospital admissions · people with COPD who have smoked for ≥ 10 pack‐years

Tiotropium showed no clear difference in number of patients with one or more hospitalisations for any cause compared with placebo (moderate certainty).

1 finding from 1 review

Tiotropium versus placebo for chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 1 [0.88, 1.13]
19 studies · 20963 participants
Moderate

Strong steroid (class III or IV) vs mild steroid (class I or II)

Total clearance (more than 4 weeks) Investigator's assessment · patients with seborrhoeic dermatitis

Strong steroid (class III or IV) may leads to lower total clearance (more than 4 weeks) Investigator's assessment compared with mild steroid (class I or II) (low certainty).

1 finding from 1 review

Topical anti‐inflammatory agents for seborrhoeic dermatitis of the face or scalp 2014 · Cochrane Headline outcomes only
RR 0.79 [0.63, 0.98]
1 study · 117 participants
Low

Intervention not reported

Distance‐corrected near visual acuity at 12 months or more [Jaeger units and logMAR units] · Participants over age of 21 years undergoing cataract surgery

1 finding from 1 review

Accommodative intraocular lens versus standard monofocal intraocular lens implantation in cataract surgery 2014 · Cochrane Headline outcomes only
no estimate extracted
111 participants
Low

Intervention not reported

Corrected distant visual acuity at 12 months or more [logMAR units] · Participants over age of 21 years undergoing cataract surgery

1 finding from 1 review

Accommodative intraocular lens versus standard monofocal intraocular lens implantation in cataract surgery 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 70 participants
Low